Global Vyndaqel Market Size Likely to Surpass at a CAGR of 15.8% By 2033

As per the current market research conducted by CMI Team, the global Vyndaqel Market size is expected to record a CAGR of 15.8% from 2023 to 2032. In 2022, the market size is projected to reach a valuation of USD 1.5 billion. By 2032, the valuation is anticipated to reach USD 9.2 billion.

Vyndaqel Market: Growth Factors and Dynamics

• Disease Prevalence and Awareness: Increasing recognition of transthyretin amyloidosis and improved diagnostics have led to a growing patient pool. As awareness of the disease spreads among healthcare providers and the public, the demand for effective treatments like Vyndaqel continues to rise.

• Advancements in Medical Research: Ongoing research in the field of amyloidosis and RNA-based therapies has paved the way for innovative treatments like Vyndaqel. Scientific breakthroughs and clinical trials contribute to market growth by expanding treatment options.

• Regulatory Approvals: Vyndaqel’s approval by regulatory agencies in various regions has provided a solid foundation for its market presence. Regulatory support not only ensures patient safety but also enhances the drug’s credibility and accessibility.

• Strategic Collaborations: Partnerships between pharmaceutical companies, such as Pfizer and Akcea Therapeutics, enable the development, distribution, and marketing of Vyndaqel. These collaborations streamline the drug’s availability to a broader patient population.

• Patient Access and Support Programs: Initiatives to improve patient access, affordability, and adherence to Vyndaqel therapy contribute to its market growth. Support programs and financial assistance options help patients receive the treatment they need.

• Global Expansion: Efforts to expand Vyndaqel’s availability in different regions and countries increase its market reach. This includes securing regulatory approvals in new markets and addressing unmet medical needs.

• Competitive Landscape: While Vyndaqel currently dominates the market, competition from emerging therapies and innovative treatments may drive advancements and further market expansion.

• Healthcare Policies: Favorable healthcare policies, such as orphan drug designations and reimbursement incentives, can facilitate the growth of Vyndaqel’s market by making the drug more accessible to patients and healthcare providers.

Vyndaqel Market: Partnership and Acquisitions

• Pfizer and Intellia Therapeutics: Intellia Therapeutics, a trailblazing gene editing firm, is progressing with NTLA-2001, a CRISPR/Cas9-based gene therapy that targets the TTR gene in the context of ATTR-CM. In 2022, Pfizer and Intellia Therapeutics unveiled a collaborative venture to jointly develop and bring NTLA-2001 to the market.

• Pfizer and Novartis: Novartis, a global pharmaceutical leader with a strong presence in cardiovascular treatments, is diligently crafting vutrisiran (ALN-TTRsc) as a remedy for ATTR-CM. In 2022, Pfizer and Novartis announced a strategic partnership to co-create and commercially introduce vutrisiran, demonstrating their shared commitment to advancing therapies for this condition.

• Pfizer and Ionis Pharmaceuticals: Ionis Pharmaceuticals, renowned for its RNA-targeted therapeutic innovations, is at the forefront of developing eplontersen (IONIS-TTR-LRx) for ATTR-CM. In 2021, Pfizer and Ionis Pharmaceuticals forged a collaboration, signalling their joint efforts in developing and bringing eplontersen to the market to address transthyretin amyloid cardiomyopathy.

Report Scope

Vyndaqel Market: COVID-19 Analysis

The COVID-19 pandemic has significantly impacted the Vyndaqel Market.

• Supply Chain Disruptions: The pandemic disrupted global supply chains, affecting the manufacturing and distribution of pharmaceuticals, including Vyndaqel. This led to potential delays in the availability of the drug in certain regions.

• Clinical Trials: Clinical trials for Vyndaqel and other drugs faced disruptions due to lockdowns, social distancing measures, and reduced patient enrollments. This may have impacted the timeline for new drug approvals and expanded indications.

• Patient Access: Lockdowns and restrictions on healthcare facilities affected patients’ access to healthcare services, potentially impacting their ability to receive Vyndaqel or engage in regular check-ups.

• Telemedicine and Remote Monitoring: The pandemic accelerated the adoption of telemedicine and remote monitoring technologies. This could positively impact Vyndaqel’s market, as it facilitates remote consultations, prescription refills, and monitoring for patients.

• Healthcare Spending and Budgets: The economic impact of the pandemic led to budget constraints in healthcare systems. This may have influenced decisions related to drug reimbursement and accessibility.

• R&D Investments: Despite challenges, the urgency of addressing COVID-19 prompted increased investments in pharmaceutical research and development. This indirectly contributed to advancements in the broader field of medicine, potentially benefiting Vyndaqel’s development.

• Increased Focus on Rare Diseases: The pandemic heightened awareness of the importance of addressing rare diseases and fostering healthcare resilience. This could lead to greater emphasis on treatments like Vyndaqel.

• Vaccination Campaigns: As vaccination campaigns progress globally, the control of COVID-19 may lead to a more stable healthcare environment, potentially benefiting the Vyndaqel market.

In summary, while the COVID-19 pandemic presented challenges, it also highlighted the importance of pharmaceutical innovation and healthcare preparedness. The long-term impact on the Vyndaqel market will depend on how these trends evolve and how healthcare systems adapt to the lessons learned during the pandemic.

List of the prominent players in the Vyndaqel Market:

• Pfizer Inc. (manufacturer of Vyndaqel)
• Ionis Pharmaceuticals Inc. (involved in the development of tafamidis)
• Akcea Therapeutics Inc. (a subsidiary of Ionis Pharmaceuticals)
• Alnylam Pharmaceuticals Inc.
• Alnylam Europe AG
• Alnylam UK Ltd.
• Alnylam Ireland Ltd.
• Alnylam France S.A.S.
• Alnylam Germany GmbH
• Alnylam Netherlands B.V.
• Others

The Vyndaqel Market is segmented as follows:

By Disease Type

• Familial amyloid polyneuropathy (FAP)
• Wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM)

By Distribution Channel

• Hospital Pharmacies
• Specialty Pharmacies
• Retail Pharmacies

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America